KORU Medical Q1 2026 slides: 22% revenue growth beats forecast

KORU Medical reported Q1 2026 revenue of $11.8 million, up 22% year over year and above the $11.23 million consensus, while narrowing net loss to $0.8 million and improving adjusted EBITDA to -$0.01 million. Gross margin was 61.5%, down 130 bps due to production timing and tariff charges, but management reaffirmed full-year 2026 guidance for $47.5 million to $50 million in revenue and 61%-63% gross margin. The company also highlighted progress in its non-Ig pipeline, including a 510(k) submission for deferoxamine and two collaborations advancing to Phase III.

Analysis

KRMD’s better-than-expected top line matters less for the headline beat than for what it implies about mix durability: the business is showing operating leverage in a market where incremental consumables should compound once patient starts convert into repeat usage. The key second-order effect is that international PFS conversion can become a self-reinforcing channel expansion loop — each new geography not only adds revenue, but increases the installed-base proof point that pharma partners need before signing additional collaborations.

The margin story is the real fulcrum. Tariffs are acting like a temporary tax on a scaling story, but the fact that normalized gross margin is roughly flat suggests pricing and manufacturing are not broken; if tariff pressure eases or sourcing is re-optimized, there is room for a fast step-up in EBITDA without heroic revenue assumptions. That makes the next 2-3 quarters more important than the next 2-3 years: a clean Q2 cash-usage peak and second-half cash inflection would likely force re-rating from “small-cap story” to “self-funding growth platform.”

Consensus still seems to be underappreciating governance/event risk around the CEO transition. In a name this size, execution continuity matters more than strategic vision, and the market will likely punish any wobble in pipeline conversion or international launch timing. The contrarian view is that the stock is not cheap on current earnings power, but it may still be undervalued on option value if even one or two non-Ig programs progress into repeatable commercial relationships; the asymmetry is in pipeline validation, not in current quarter numbers.

Key Decisions for Investors

• Long KRMD into any post-print consolidation, with a 3-6 month horizon: downside is likely bounded unless guidance is cut, while successful H2 cash-flow inflection can re-rate the stock toward the low end of the $5-$8 target range.
• Use call spreads rather than outright stock: buy KRMD 6-9 month call spreads struck around the current share price to capture pipeline/launch upside while limiting dilution and governance risk.
• Pair trade: long KRMD / short a slower-growing medtech supplier with heavier tariff exposure over the next 1-2 quarters; the trade works if KRMD’s gross margin stays stable while peers absorb input-cost pressure.
• If KRMD rallies on management succession headlines, trim into strength until the new CEO demonstrates continuity on pipeline approvals and EU execution; key risk window is the next 2 earnings calls.
• For event-driven accounts, add only on evidence of a second international win or additional 510(k) clearance; those catalysts are more powerful than the revenue beat and would materially improve valuation confidence.